Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

1. KROS initiated a review for strategic alternatives, possibly involving a sale. 2. A new stockholder rights plan has been adopted to protect investors. 3. An individual now owns 11.2% of Keros, indicating strong investor interest. 4. KER-065 shows therapeutic potential for muscular diseases, backed by initial trial results. 5. Keros has a strong cash position, ensuring runway till 2029.